Current stock page

Stock Analysis

TG Therapeutics, Inc. (TGTX) Stock Analysis

TG Therapeutics, Inc. (TGTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TGTX Stock Analysis Summary

TG Therapeutics, Inc. (TGTX) currently has an AIQ Score of 76/100, indicating a bullish setup. Momentum is the strongest factor at 93/100. Risk is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TGTX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$64.51
AIQ Score76/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$9.08B
P/E Ratio (TTM)86.6
Forward P/E—
EPS (Q3 FY2026)$0.39
Revenue (Q3 FY2026)$259.94M
Dividend Yield (TTM)0.00%
Beta0.68
Volume1.1M
52-week range$26.76-$68.03
RSI 1465.39
50-Day SMA$56.69
200-Day SMA$45.38
Analyst Price Target—
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

TGTXTG Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$64.51−$0.05 (−0.08%)

Latest quote

  • Momentum
    93
  • Value
    65
  • Quality
    69
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TGTX Stock Analysis Summary

TG Therapeutics, Inc. (TGTX) currently has an AIQ Score of 76/100, indicating a bullish setup. Momentum is the strongest factor at 93/100. Risk resilience is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, TGTX has AIQ Score of 76/100 with Momentum base of 93/100 and fading Risk resilience at 63/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (93/100) leads while Risk resilience (63/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.08% stock move · TGTX classified in Biotechnology.

Current Evidence

BullishTGTX is in a bullish AIQ regime; Momentum is the strongest visible factor at 93/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TGTX Bullish or Bearish Right Now?

TGTX currently has a bullish overall setup. Momentum is the strongest factor at 93/100, while Risk Resilience is weakest at 63/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 69/100.
  • - Momentum is constructive at 93/100.
  • - Price is +13.78% above its 50-day SMA.
  • - Technical consensus has more buy votes than sell votes (36 vs 2).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

TGTX's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 8 neutral, and 2 sell votes. TGTX's 14-day RSI is 65.39, which places the stock in a constructive momentum range. TGTX's beta is 0.68, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in TGTX?

The largest recent change in TGTX is Quality moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+2.0
Quality
+4.0
Risk
-1.0

What Would Change the TGTX Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TGTX Decision Framework

Public evidence layers, setup checks, and risk context for TG Therapeutics, Inc..

TG Therapeutics, Inc. (TGTX) Stock Analysis

TG Therapeutics, Inc. has an AIQ Score of 76/100 in a Bullish regime. Momentum is strongest at 93/100. Beta is 0.68, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTGTX is in a Bullish AIQ regime with score 76/100.
Signal ConflictThe primary conflict is that momentum leads at 93/100 while risk lags at 63/100.
Factor EvidenceMomentum 93/100 · Value 65/100 · Quality 69/100 · Risk 63/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 93/100.

TimingPass

Momentum is 93/100 and RSI (14) is 65.4.

Regime fitPass

TGTX is in a Bullish regime at 76/100.

Risk controlWait

Risk factor is 63/100 with beta 0.68 and annual volatility 46.06%.

ConflictWait

Current conflict: momentum leads at 93/100 while risk lags at 63/100.

AIQ Score
76/100
Price
$64.51
Beta
0.68
RSI (14)
65.4

TGTX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TGTX Fundamentals

TGTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$259.94M
Net income
$55.46M
Free cash flow
$44.95M
View full TGTX fundamental analysis

TGTX Technical Analysis

TGTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
65.39
Price vs SMA-50
+13.78%
View full TGTX technical analysis

TGTX Stock Catalysts

Track TGTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
—
News items
5
View TGTX earnings and stock catalysts

TGTX Dividend Analysis

TGTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TGTX dividend history and analysis

TGTX Financial Data

TGTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$259.94M
EPS
$0.39
Periods
8
View TGTX financials

TGTX Risk Analysis

TGTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.68
Risk score
63/100
1Y volatility
46.06%
View TGTX risk analysis

TGTX Stock News

TGTX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read TGTX stock news

TGTX vs Biotechnology Peers

Current peer cohort: TGTX · TNGX · TRVI · TSHA · TVTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TGTX
Current stock
76/10065/10093/10063/1001.7446.06%Current
TNGX
Tango Therapeutics, Inc.
61/100—60/10038/1001.61101.07%TGTX vs TNGX
TRVI
Trevi Therapeutics, Inc.
63/100—52/10051/1000.5259.27%TGTX vs TRVI
TSHA
Taysha Gene Therapies, Inc.
35/100—32/10037/1000.3270.69%TGTX vs TSHA
TVTX
Travere Therapeutics, Inc.
64/10069/10067/10055/1000.8762.28%TGTX vs TVTX
Pairwise Compare links: TNGX · TRVI · TSHA · TVTXTGTX vs TNGXTGTX vs TRVITGTX vs TSHATGTX vs TVTXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TGTX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TGTX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
86.6
As of Nov 13, 2026
Revenue growth
60.74%
Gross margin
82.74%
Current debt / equity
1.32
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$259.94M
Quarter net income
$55.46M
Quarter free cash flow
$44.95M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
65.39
MACD
2.53

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
63/100
Beta
0.68
Annual volatility
46.06%
Max drawdown
-21.83%

TGTX Stock FAQ

What is TGTX stock price today?

TG Therapeutics, Inc.'s current stock price is $64.51. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TGTX bullish or bearish right now?

TGTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TGTX's market cap?

TGTX's market cap is $9.08B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TGTX's current P/E ratio?

TGTX's current P/E ratio is 86.6 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TGTX's RSI?

TGTX's 14-day RSI is 65.39 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TGTX above its 50-day and 200-day moving averages?

TGTX is 13.78% from its 50-day SMA and 42.16% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TGTX's next earnings date?

TGTX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TGTX pay a dividend?

TGTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.